Objective: Abnormalities of the melanocortin system produce obesity and increased linear growth. While the obesity phenotype is well characterised, the mechanism responsible for increased linear growth is unclear. The somatotrophic axis was studied in the obese agouti (A y /a) mouse as a model of a perturbed melanocortin system. Design: Adult obese A y /a mice were compared to age-and sex-matched wild-type (WT) controls. Weight and body length (nose-anus) were recorded. Plasma growth hormone (GH), insulin-like growth factor-I (IGFI), insulin and leptin were measured using radioimmunoassay. Since ghrelin is a potent GH secretagogue, plasma ghrelin, stomach ghrelin peptide and stomach ghrelin mRNA expression were studied. Hypothalamic periventricular (PeVN) somatostatin neurones and arcuate (Arc) neuropeptide Y (NPY) neurones inhibit the growth axis, whereas Arc growth hormone-releasing hormone (GHRH) neurones are stimulatory. Therefore, specific hypothalamic expression of somatostatin, NPY and GHRH was measured using quantitative in situ hybridisation. Results: Obese A y /a mice were significantly heavier and longer than WT controls. Plasma IGFI concentrations were 30% greater in obese A y /a mice. Obese A y /a mice were hyperinsulinaemic and hyperleptinaemic, yet plasma ghrelin, and stomach ghrelin peptide and mRNA were significantly reduced. In obese A y /a mice, PeVN somatostatin and Arc NPY mRNA expression were reduced by 50% compared to WT controls, whereas Arc GHRH mRNA expression was unchanged. Conclusion: Increased body length in adult obese A y /a mice may result from reduced Arc NPY and PeVN somatostatin mRNA expression, which in turn, may increase plasma IGFI concentrations and upregulate the somatotrophic axis.
Introduction
Recent studies in obese rodents and humans have demonstrated a role for the melanocortin system in the regulation of energy homeostasis (for review see Schwartz et al. 1 ). Within this system, Agouti-related protein (AgRP), the endogenous antagonist at melanocortin-3 and -4 receptors (MC3-and MC4-Rs), stimulates feeding, 2,3 whereas alphamelanocyte-stimulating hormone (a-MSH), the endogenous agonist for these receptors, reduces food intake. The a-MSH precursor, pro-opiomelanocortin (POMC), is expressed in a population of arcuate nucleus (Arc) neurones distinct from those expressing AgRP. Transgenic mice overexpressing AgRP, 2,4 deficient in POMC 5 or deficient in the MC4-R 6 display a phenotype of hyperphagia and obesity. Similarly, pathogenic MC4-R mutations are the most common monogenic form of obesity in man. 7 Increased linear growth is a less well-characterised feature of abnormal melanocortin signalling. Humans who are obese secondary to MC4-R mutations 8 or POMC deficiency 9 are tall. Similarly, murine models of AgRP overexpression, 2, 4 POMC deficiency 5 and MC4-R deficiency 6 display increased body length. Nevertheless, recent in vivo studies of either acute 10 or chronic 11, 12 central nervous system (CNS) administration of MC3/4-R agonists or antagonists do not support a role for the melanocortin system in the regulation of the somatotrophic axis.
Longitudinal growth is regulated by growth hormone (GH) and its tissue mediator insulin-like growth factor-I (IGFI) (for review see Le Roith et al. 13 ). GH release from the anterior pituitary is under the reciprocal control of the hypothalamic hormones growth hormone-releasing hormone (GHRH) and somatostatin. GHRH, synthesised in the Arc, stimulates GH release. Hypophysiotrophic somatostatin neurones located in the periventricular nucleus (PeVN) inhibit GH release.
14 Signals regulating energy balance have also been implicated in the regulation of the somatotrophic axis, suggesting that coordinated regulation of growth occurs when energy stores are sufficient. Systemically administered ghrelin stimulates food intake and is a potent GH secretagogue (GHS) in rats and humans. 15, 16 Leptin, a signal of body adiposity, may promote longitudinal skeletal growth, since leptin-deficient obese (ob/ob) and diabetic (db/db) mice, with disrupted leptin signalling, display reduced linear growth. 17 Leptin may achieve this effect via direct effects on cartilage and bone 18, 19 and also via CNS regulation of the somato- 
Materials and methods
Animals C57BL/6J (wild type (WT)) and C57BL/6J-A y (A y /a) mice were purchased from Jackson Laboratories, ME, USA. A breeding colony was established and all mice used in these studies were derived from this colony. Mice were maintained in individual cages under controlled temperature (21-231C) and light conditions (lights on 0700-1900) with ad lib access to food (RM3 diet, SDS UK Ltd) and water unless stated otherwise. A significant difference in body weight between male WT and A y /a mice was first evident at 11 weeks of age. We therefore chose to study 12- Hypothalamic and pituitary peptide extraction and measurement Hypothalamic peptides were extracted by boiling whole hypothalami at 1001C for 10 min in 1 ml 0.5 M acetic acid. Hypothalamic somatostatin peptide content was measured by RIA as previously described. 24 Pituitary hormones were extracted by homogenisation in 500 ml of 1 M PBS urea and pituitary GH peptide content measured by RIA using reagents and methods provided by the NIDDK and the National Hormone and Pituitary Program as previously described. 25 Hypothalamic somatostatin peptide content and pituitary GH peptide content values were adjusted for extract protein content measured using a bicinchoninic acid (BCA) protein assay (Sigma Aldrich, UK).
Plasma hormone measurement
Plasma GH was measured using the RIA described above. Serum total IGFI was measured by commercial RIA after acid-ethanol extraction of binding proteins (Diagnostic Systems Laboratories Inc., TX, USA) according to the manufacturer's instructions. Plasma leptin and plasma insulin (Linco Research Inc., St Charles, MO, USA) were also measured using commercial RIAs according to the manufacturer's instructions. Plasma ghrelin was measured using an in-house RIA.
Stomach ghrelin measurement
For each animal, ghrelin peptide content was measured in one longitudinal stomach half and ghrelin mRNA expression in the other. For measurement of stomach ghrelin peptide content, stomach sections were boiled at 1001C for 10 min in 1 ml 0.5 M acetic acid and ghrelin peptide content measured as described below. Stomach ghrelin peptide content was adjusted for tissue protein content using a BCA protein assay. Stomach ghrelin mRNA expression was measured using a solution hybridisation assay as previously described for other mRNA transcripts. 26 Stomach halves were homogenised in 10 mM Tris-HCl, pH 7.5, containing 1% SDS and 5 mM EDTA
The somatotrophic axis of the obese agouti mouse NM Martin et al (SET buffer). Total nucleic acid (TNA) was extracted with phenol/chloroform, ethanol precipitated and the pellets dissolved in 0.2 Â SET buffer. The prepro-ghrelin riboprobe corresponded to exons 2 and 3 of mouse pre-proghrelin cDNA (accession number: AB035701). Briefly, TNA samples (10-50 mg) were hybridised in duplicate with 35 S-labelled prepro-ghrelin cRNA probe (20 000-30 000 cpm) at 601C overnight in 40 ml 21nM Tris-HCl, pH 7.5, containing 600 nM NaCl, 4.5 mM EDTA, 7.5 mM dithiothreitol, 0.1% SDS and 25% formamide. Standard tubes contained known quantities of target RNA, transcribed from the sense strand of the prepro-ghrelin plasmid and quantified by absorption at 260 nm. After digestion with RNase A (40 mg) and RNase T1 (2 mg), protected fragments were precipitated with 10% trichloroacetic acid, collected by filtration and detected by scintillation counting.
Ghrelin RIA Plasma ghrelin and stomach ghrelin peptide content were measured using a specific and sensitive RIA described previously. 27 The assay detected changes of 25 pmol/l of plasma ghrelin with 95% confidence limit, with an interassay coefficient of variation 5.5%.
In situ hybridisation Animals were killed as described above and the brains frozen on dry ice. Sections were cut at À161C, thaw mounted onto gelatin-and chrome alum-coated slides, and stored at À701C. In situ hybridisation for somatostatin, GHRH and NPY was performed on 12 mm coronal sections through a variety of brain regions including the PeVN and Arc. Frozen sections were thawed at room temperature, fixed in 4% paraformaldehyde, acetylated, dehydrated through ethanol solutions and delipidated in chloroform before hybridisation overnight at 451C as previously described. 28 Following posthybridisation washes and digestion with RNase, slides were air dried, apposed to autoradiographic film (BioMax MR, Kodak, Rochester, NY, USA) for up to 1 week. 28 X-ray images were analysed densitometrically using NIH Image software (http://rsb.info.nih.gov/nih-image/). For each mouse two to four anatomically matched sections (identified by counterstaining with cresyl violet) were analysed for each probe, with data generated in the form of integrated optical density, in arbitrary units. All comparisons were made within the same experiment/hybridisation. Radiolabelled probes were synthesised as previously described. 29 Since NPY and somatostatin are highly homologous in rats and mice, rat NPY and somatostatin riboprobes were used. The somatostatin riboprobe was a 276 base pair (bp) fragment of rat somatostatin cDNA, corresponding to nucleotides 280-556 of rat somatostatin full-length cDNA (accession number: NM_012659). The NPY riboprobe was a 370 bp fragment of rat NPY corresponding to nucleotides 79-449 of the full-length rat NPY cDNA (accession number: NM_012614). The mouse GHRH riboprobe corresponded to nucleotides 79-356 of mouse hypothalamic GHRH cDNA (accession number: NM_031577). Sense control slides were run in each hybridisation to confirm signal specificity. No significant sense binding was observed in any of the probes used on adjacent sections. The methods used have been previously validated 30 and reflect the findings using silver grain counting.
Statistical analysis
All data are expressed as mean7s.e.m. Differences in mean values between genotypes were determined using the Student's t-test for unpaired data. Nonparametric data (PeVN somatostatin mRNA expression and Arc NPY mRNA expression) were compared using the Mann-Whitney rank sums method. Po0.05 was considered statistically significant.
Results
Body weight and body length in obese A y /a mice (Figure 1c) . However, hypothalamic somatostatin peptide content was significantly reduced in obese A y /a mice (Po0.005) (Figure 1d ).
Plasma insulin and leptin
In accord with previously described results, 31 (Figures 2a and b) . Consistent with the reduction in peptide content, stomach ghrelin mRNA expression was significantly lower in obese A y /a mice compared to WT mice (stomach ghrelin mRNA: Po0.05) (Figure 2c ). 
Discussion
Although increased linear growth is a well-documented characteristic of the obese A y /a mouse, 34 would be expected to result in increased plasma GH and hence IGFI. In accord with this, plasma IGFI and GH concentrations were increased in obese A y /a mice, although the latter not significantly. Since GH release is pulsatile, this makes a single plasma GH measurement difficult to interpret. However, owing to the small circulating blood volume in mice, it is not technically possible to perform sequential sampling of plasma GH. Measurements of free IGFI and/or IGF-binding proteins would be interesting, although these are also currently technically difficult in the mouse. Arc GHRH mRNA expression in obese A y /a mice was unchanged, suggesting that increased linear growth in these mice may be largely independent of GHRH.
Stomach and plasma ghrelin concentrations were reduced in obese A y /a mice. Therefore, this makes it unlikely that ghrelin contributes to their increased linear growth. In other murine models of abnormal melanocortin signalling, plasma and stomach ghrelin concentrations have not been described. A reduction in plasma ghrelin in the obese A y /a mouse is consistent with the low plasma ghrelin found in obese humans.
37-39
The reduction in Arc NPY mRNA expression in obese A y /a mice may contribute to their increased linear growth. Our observation is in contrast to a previous study of obese A y /a mice of a comparable age and body weight that used similar techniques. 40 48 and it has been proposed that hyperinsulinaemia is responsible for increased growth in children with simple obesity 49 or obesity secondary to MC4-R deficiency. 8 However, since ob/ob mice have increased plasma insulin, yet are short, 17 it seems unlikely that hyperinsulinaemia alone is responsible. In support of this, A y /a mice aged 3-4 weeks have increased plasma IGFI concentrations, 35 yet are not hyperinsulinaemic at this age. 50 Further study of young, preobese A y /a mice may reveal at what age somatotrophic changes occur.
The fact that our current observations merely reflect changes secondary to obesity per se must be considered. However, in diet-induced obesity, which is associated with raised plasma insulin and leptin, reports of Arc NPY mRNA expression are conflicting. 51, 52 Nevertheless, PeVN somatostatin mRNA expression in diet-induced obesity is increased, 53 which is in direct contrast to our current findings in obese A y /a mice. Hyperleptinaemia in obese A y /a mice may reduce Arc NPY mRNA expression, as plasma leptin and Arc NPY mRNA expression are inversely related. 54 However, this cannot explain the observed reduction in PeVN somatostatin mRNA expression in obese A y /a mice, since leptin stimulates PeVN somatostatin mRNA expression. 55 Therefore, not all of our findings are consistent with changes associated with diet-induced obesity. Although hyperleptinaemia and hyperinsulinaemia may contribute to increased linear growth in obese A y /a mice, the reduced Arc NPY and PeVN somatostatin mRNA expression observed in these mice may be primary, rather than secondary abnormalities. Although recent studies involving MC3-and/or MC4-R stimulation and antagonism do not support involvement of the melanocortin system in regulating the somatotrophic axis, [10] [11] [12] these studies differ from the current investigations in several ways. Firstly, MC3-and/or MC4-R antagonism was studied for only 7 days, 11 compared to the chronic, endogenous MC4-R antagonism present throughout the life of the obese A y /a mouse. Secondly, the current study measured somatostatin and NPY mRNA expression in specific hypothalamic areas, rather than in whole hypothalami. Arc NPY neurones only express the MC3-R 56 and so it is unlikely that reduced Arc NPY mRNA expression in obese A y /a mice directly reflects MC4-R antagonism by agouti protein.
Although there is dense MC4-R mRNA expression in the PeVN, 57 it is not clear whether PeVN somatostatin neurones express MC4-R. Decreased PeVN somatostatin mRNA expression in obese A y /a mice therefore may be secondary to abnormal MC4-R signalling. Since the MC3-R null mouse does not display increased body length, 58, 59 this suggests that it is abnormal signalling through the MC4-R, not the MC3-R, that increases linear growth. Based on the current findings, we propose a hypothetical model to suggest an underlying mechanism for the characteristic increase in somatic growth in obese A y /a mice (shown schematically in Figure 5 ). In this model, leptin signals from the periphery to the CNS to indicate that energy stores are sufficient to allow coordinated regulation of growth via reduced Arc NPY signalling. Reduced PeVN somatostatin mRNA expression may be regulated directly,
The somatotrophic axis of the obese agouti mouse NM Martin et al possibly via the MC4-R or, indirectly, via a reduction in Arc NPY mRNA expression. Since somatostatin is the endogenous inhibitor of the somatotrophic axis, such a reduction would increase plasma IGFI, as observed in obese A y /a mice.
These CNS mechanisms may contribute to the characteristic increase in linear growth observed in models of abnormal melanocortin signalling.
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